US Broker Ratings

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 21% Potential Upside in the Healthcare Sector

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a notable player in the healthcare sector, has captured investor attention with its robust pipeline of pain management medications and promising financial metrics. With a..

Talkspace, Inc. (TALK) Stock Analysis: Exploring a 35% Upside Potential and Strong Buy Ratings

For investors looking to navigate the dynamic field of healthcare technology, Talkspace, Inc. (NASDAQ: TALK) presents a compelling opportunity. Positioned within the burgeoning sector of virtual behavioral healthcare, Talkspace offers..

OrthoPediatrics Corp. (KIDS) Stock Analysis: A 34.91% Potential Upside Amid Strong Buy Ratings

OrthoPediatrics Corp. (NASDAQ: KIDS), a pioneering player in the healthcare sector focused on pediatric orthopedic solutions, stands at a pivotal juncture for investors with a potential upside of 34.91%. This..

Owens & Minor, Inc. (OMI) Stock Analysis: Is the 94% Potential Upside Worth the Risk?

Owens & Minor, Inc. (NYSE: OMI), a notable player in the healthcare sector specializing in medical distribution, presents a compelling narrative for investors with its standout potential upside of 94.29%...

uniQure N.V. (QURE) Stock Analysis: A Potential 210% Upside in the Biotechnology Sector

For investors with an eye on the biotechnology sector, uniQure N.V. (QURE) is a fascinating opportunity. Headquartered in Amsterdam, this Dutch company is a prominent player in the healthcare industry,..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A 41.98% Potential Upside Beckons Investors

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a Massachusetts-based clinical-stage pharmaceutical company, is causing a stir in the healthcare sector with its focus on cutting-edge treatments for neurodegenerative diseases and endocrine conditions...

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) presents a compelling investment opportunity in the biotechnology sector, with a potential upside of 14.37%, according to current analyst ratings. With a market capitalization..

AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal a 22.88% Upside Potential

AxoGen, Inc. (NASDAQ: AXGN), a key player in the healthcare sector specializing in medical devices for peripheral nerve regeneration and repair, has been drawing significant attention from investors. With a..

AnaptysBio, Inc. (ANAB) Stock Analysis: A Biotech with 21% Potential Upside

AnaptysBio, Inc. (ANAB) has recently emerged as a compelling opportunity for investors in the biotech sector, particularly those with an eye for innovative developments in immunology therapeutics. Based in San..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine

Relay Therapeutics, Inc. (RLAY) is capturing investor attention with its position as a clinical-stage precision medicines company in the biotechnology industry. With a market capitalization of $1.59 billion, this Cambridge,..

Simulations Plus, Inc. (SLP) Stock Analysis: A 104% Potential Upside Despite Recent Headwinds

Simulations Plus, Inc. (NASDAQ: SLP) stands at an intriguing crossroads for investors, offering a blend of advanced technological solutions in health information services with significant potential upside. Despite recent challenges,..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a dynamic player in the biotechnology sector, is catching the eye of many investors due to its ambitious pursuit of innovative cancer treatments and a..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating Uncertain Waters with a Potential Downside

Community Health Systems, Inc. (NYSE: CYH), a prominent player in the healthcare sector, operates an extensive network of general acute care hospitals across the United States. Despite its substantial presence..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Potential Upside of 132% Amid Rising Investor Interest

Iovance Biotherapeutics, Inc. (IOVA), a key player in the biotechnology sector, has been capturing the attention of investors with its innovative approach to cancer treatment. As a commercial-stage biopharmaceutical company,..

Geron Corporation (GERN) Stock Analysis: Eyeing a 106% Potential Upside in the Biotech Arena

For investors with an appetite for high-stakes opportunities in the biotechnology sector, Geron Corporation (NASDAQ: GERN) stands out as a compelling prospect. With a market capitalization of $1.05 billion, this..

Nuvation Bio Inc. (NUVB) Stock Analysis: A Biotech Gem with 104.98% Upside Potential

Nuvation Bio Inc. (NUVB) has been attracting attention in the biotech sector, not least because of its significant upside potential of 104.98%, according to analyst ratings. As a clinical-stage biopharmaceutical..

InMode Ltd. (INMD) Investor Outlook: Exploring a 19.57% Potential Upside in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD), a key player in the medical devices industry, has been capturing attention with its innovative aesthetic medical products. Headquartered in Yokne’am, Israel, and boasting a market..

AMN Healthcare Services Inc (AMN): Investor Outlook Highlights 16% Potential Upside

AMN Healthcare Services Inc (AMN) stands as a key player within the healthcare sector, specifically in the medical care facilities industry. With a market capitalization of $735.24 million, AMN provides..

Oculis Holding AG (OCS) Stock Analysis: A Promising 52.55% Upside Potential in the Biotech Sector

Oculis Holding AG (OCS), a Switzerland-based clinical-stage biopharmaceutical company, is capturing investor attention with its promising pipeline of ophthalmic treatments and impressive upside potential. Operating within the healthcare sector, specifically..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 71% Upside Potential

Rocket Pharmaceuticals, Inc. (RCKT), a pioneering entity in the biotechnology sector, is capturing attention with its promising pipeline of gene therapies targeting rare and life-threatening diseases. With a market capitalization..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds